First Direct Thrombin Inhibitor for DVT Prevention Now Available From Canyon Pharmaceuticals

Published: Mar 01, 2010

PARSIPPANY, N.J.--(BUSINESS WIRE)--Canyon PharmaceuticalsTM (www.canyonpharma.com) today announced the availability of Iprivask (desirudin for injection), the first direct thrombin inhibitor (DTI) approved in the United States by the Food and Drug Administration (FDA) for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism in patients undergoing elective hip replacement surgery.

Back to news